# Major Recall Alert: Doxorubicin Liposomal Recalled Due to Presence of Particulate Matter
A recent recall has been issued for **Doxorubicin Liposomal**, a chemotherapy drug marketed under the **Taro brand**, due to a serious contamination concern. Health Canada has announced that an affected lot of the medication may contain **particulate matter**, which can pose significant health risks if administered. This recall underscores the importance of ensuring the safety of pharmaceutical products for patients relying on them. Read on for all the critical details about the recall and how you can stay protected.
## Why This Recall is Important
Doxorubicin Liposomal is commonly used to treat various types of cancer, including breast cancer, ovarian cancer, and multiple myeloma. Contamination of this lifesaving medication with particulate matter can pose serious health risks — particularly for already vulnerable cancer patients. When injection drugs contain particulate matter, potential dangers include:
- Vein irritation or inflammation at the injection site.
- Complications such as vein blockages or blood vessel damage.
- Risk of life-threatening infections or inflammation in vital organs.
Pharmaceutical recalls like this aim to immediately protect patients from potential harm. If you or a loved one uses Doxorubicin Liposomal, it’s vital to stay informed about the recall details and take swift action.
## Details of the Recall
The recall for Taro's Doxorubicin Liposomal was officially announced on **29292**. Here’s what you need to know:
- **Product Name**: Doxorubicin Liposomal
- **Brand**: Taro
- **Reason for Recall**: Presence of particulate matter in the affected lot.
- **Category**: CAN (Canada)
- **Manufacturer Action**: The affected lot has been recalled to prevent exposure.
Health Canada has publicly shared this recall notice to raise awareness among patients, healthcare providers, and pharmacists. For further information, you can review the official recall notice [here](https://recalls-rappels.canada.ca/en/alert-recall/taro-doxorubicin-liposomal-may-contain-particulate-matter).
## What You Should Do
If you are currently using or have been prescribed Doxorubicin Liposomal, here’s how to respond to this urgent recall:
1. **Check Your Medication**: Review the packaging and lot number of your Doxorubicin Liposomal to see if it matches the affected batch. Contact your pharmacist if you’re unsure.
2. **Stop Use Immediately**: If you have medication from the recalled lot, do not use it. Reach out to your healthcare provider for guidance on safe alternatives and replacement options.
3. **Report Incidents**: Patients and healthcare professionals are encouraged to report any adverse reactions or quality concerns to Health Canada.
4. **Consult Your Doctor**: Discuss your treatment plan with your healthcare provider to ensure safety and continuity of care.
## Stay Safe – Get Instant Recall Alerts
Pharmaceutical recalls, such as the one concerning Taro’s Doxorubicin Liposomal, remind us how vital it is to stay vigilant about the medications we use. To ensure you never miss an important recall, download our **recall alert app**. With instant notifications and reliable updates, we’ll help you protect yourself and your loved ones from safety risks.
**Click below and download the app now to stay informed and proactive.**
[Download Now]
In today’s complex healthcare landscape, staying informed is your best safeguard. For complete details about this recall, visit the **official notice from Health Canada** [here](https://recalls-rappels.canada.ca/en/alert-recall/taro-doxorubicin-liposomal-may-contain-particulate-matter). Stay safe and share this information with others who may benefit!